Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

Authors Huang CC, Charng MJ

Received 14 July 2019

Accepted for publication 1 October 2019

Published 15 October 2019 Volume 2019:15 Pages 1209—1216

DOI https://doi.org/10.2147/TCRM.S193971

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Deyun Wang


Chin-Chou Huang,1–5 Min-Ji Charng2,3

1Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; 2Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3Faculty of Medicine, School of Medicine, National Yang–Ming University, Taipei, Taiwan; 4Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan; 5Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan

Correspondence: Min-Ji Charng
Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Taiwan, R. O. C.
Tel +886 2 28757507
Fax +886 2 28756849
Email mjcharng@vghtpe.gov.tw

Chin-Chou Huang
Department of Medical Education, Taipei Veterans General hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Taiwan, R. O. C.
Tel +886 2 28757725
Fax +886 2 28757726
Email cchuang4@vghtpe.gov.ytw

Abstract: Evolocumab, which can lower low-density lipoprotein (LDL) cholesterol levels by approximately 60% and prevent cardiovascular events in patients with cardiovascular disease, is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Some studies have investigated its efficacy and safety in the treatment of the homozygous form of familial hypercholesterolemia (HoFH), and others have focused on its efficacy and safety in Asians with high cardiovascular risk. Although no direct evolocumab clinical trials have been conducted in Chinese HoFH patients, its efficacy and safety in the Chinese population should be similar to those in other ethnic groups.

Keywords: Chinese, evolocumab, homozygous familial hypercholesterolemia, low-density lipoprotein, proprotein convertase subtilisin/kexin type 9


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]